AstraZeneca PLC at JPMorgan Healthcare Conference Transcript
Good afternoon. I'm James Gordon, JPMorgan European pharma and biotech analyst. And today, I've got the pleasure of introducing the AstraZeneca presentation. So you're going to hear from AstraZeneca CFO, Aradhana Sarin. Thank you very much for joining us today, Aradhana. Really looking forward to the presentation.
Thank you, James, and JPMorgan for hosting us this year. Good afternoon, everyone. It's a pleasure to be here with all of you to share the remarkable progress that AstraZeneca has made over the course of 2023 and explain some of the factors that underpin our confidence in delivering industry-leading growth through 2030 and beyond.
On this slide, you'll see some of our forward-looking statements, which I urge you to take a moment to review when you have a chance. This is an exciting time to be at AstraZeneca. In the first 9 months of 2023, we delivered $34 billion in revenue with ex-COVID medicines up 15%
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
